{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:20Z","timestamp":1786480280805,"version":"build-2736575974"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK058816"],"award-info":[{"award-number":["DK058816"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK090728"],"award-info":[{"award-number":["DK090728"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Robert M. and Billie Kelley Pirnie Translational PKD Center"},{"name":"Zell Family Foundation"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Asymptomatic pyuria is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene and cystic growth.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The eGFR decline occurred after detection of asymptomatic pyuria without significant changes in the rate of total kidney volume growth.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This study supports the use of asymptomatic pyuria as an enriching prognostic biomarker to predict faster disease progression.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) has phenotypic variability only partially explained by established biomarkers that do not readily assess pathologically important factors of inflammation and kidney fibrosis. We evaluated asymptomatic pyuria (AP), a surrogate marker of inflammation, as a biomarker for disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study of adult patients with ADPKD. Patients were divided into AP and no pyuria (NP) groups. We evaluated the effect of pyuria on kidney function and kidney volume. Longitudinal models evaluating kidney function and kidney volume rate of change with respect to incidences of AP were created.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 687 included patients (347 AP, 340 NP). The AP group had more women (65% versus 49%). Median ages at kidney failure were 86 and 80 years in the NP and AP groups (log rank,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.49), respectively, for patients in Mayo Imaging Class (MIC) 1A\u20131B as compared with 59 and 55 years for patients in MIC 1C\u20131D\u20131E (log rank,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02), respectively. Compared with the NP group, the rate of kidney function (ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      per year) decline shifted significantly after detection of AP in the models, including all patients (\u22121.48;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), patients in MIC 1A\u20131B (\u22121.79;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), patients in MIC 1C\u20131D\u20131E (\u22121.18;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and patients with\n                      <jats:italic toggle=\"yes\">PKD1<\/jats:italic>\n                      (\u22121.04;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Models evaluating kidney volume rate of growth showed no change after incidence of AP as compared with the NP group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AP is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth. These results support AP as an enriching prognostic biomarker for the rate of disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0004292021","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T09:50:14Z","timestamp":1638957014000},"page":"465-476","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.34067","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-2015","authenticated-orcid":false,"given":"Brian E.","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-7822","authenticated-orcid":false,"given":"Yaman G.","family":"Mkhaimer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureano J.","family":"Rangel","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroun","family":"Chedid","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-4741","authenticated-orcid":false,"given":"Phillip J.","family":"Schulte","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-3395","authenticated-orcid":false,"given":"Alaa K.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M.","family":"Neal","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Zubidat","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarjyot K.","family":"Randhawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-8696","authenticated-orcid":false,"given":"Christian","family":"Hanna","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Department of Pediatrics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana V.","family":"Gregory","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-9853","authenticated-orcid":false,"given":"Timothy L.","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-9699","authenticated-orcid":false,"given":"Ziad M.","family":"Zoghby","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-9117","authenticated-orcid":false,"given":"Sarah R.","family":"Senum","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad T.","family":"Chebib","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: Core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ekir.2020.12.016","article-title":"Characteristics of patients with end-stage kidney disease in ADPKD","volume":"6","author":"Shukoor","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1681\/ASN.V7102142","article-title":"Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2","volume":"7","author":"Torra","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease","volume":"8","author":"Johnson","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","article-title":"Incident renal events and risk factors in autosomal dominant polycystic kidney disease: A population and family-based cohort followed for 22 years","volume":"1","author":"Dicks","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/ajkd.2002.33379","article-title":"Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study","volume":"39","author":"Fick-Brosnahan","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"2054358117693355","DOI":"10.1177\/2054358117693355","article-title":"Total kidney volume as a biomarker of disease progression in autosomal dominant polycystic kidney disease","volume":"4","author":"Tangri","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/nep.12045","article-title":"Role of interstitial inflammation in the pathogenesis of polycystic kidney disease","volume":"18","author":"Ta","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/ki.1992.413","article-title":"Renal histology in polycystic kidney disease with incipient and advanced renal failure","volume":"42","author":"Zeier","year":"1992","journal-title":"Kidney Int"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1172\/JCI80467","article-title":"Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm1783","article-title":"A tumor necrosis factor-\u03b1-mediated pathway promoting autosomal dominant polycystic kidney disease","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","article-title":"Macrophages promote polycystic kidney disease progression","volume":"83","author":"Swenson-Fields","year":"2013","journal-title":"Kidney Int"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-3-319-51436-9_12","article-title":"Inflammation and fibrosis in polycystic kidney disease","volume":"60","author":"Song","year":"2017","journal-title":"Results Probl Cell Differ"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3343\/alm.2020.40.3.238","article-title":"Prevalence and clinical characteristics of asymptomatic pyuria in chronic kidney disease","volume":"40","author":"Kwon","year":"2020","journal-title":"Ann Lab Med"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20510","article-title":"The Diagnosis of Urinary Tract infection in Young children (DUTY): A diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness","volume":"20","author":"Hay","year":"2016","journal-title":"Health Technol Assess"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1410052","article-title":"Sterile pyuria","volume":"372","author":"Wise","year":"2015","journal-title":"N Engl J Med"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B33-20250825","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B35-20250825","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ki.2008.686","article-title":"Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease","volume":"75","author":"Rossetti","year":"2009","journal-title":"Kidney Int"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.kint.2019.08.038","article-title":"Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease","volume":"97","author":"Hopp","year":"2020","journal-title":"Kidney Int"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"e138724","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"key":"B39-20250825","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II alpha subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B40-20250825","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"key":"B41-20250825","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.kint.2018.06.025","article-title":"CD8+ T cells modulate autosomal dominant polycystic kidney disease progression","volume":"94","author":"Kleczko","year":"2018","journal-title":"Kidney Int"},{"key":"B42-20250825","doi-asserted-by":"crossref","first-page":"e98615","DOI":"10.15252\/embj.201798615","article-title":"Cilia-localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney","volume":"37","author":"Viau","year":"2018","journal-title":"EMBO J"},{"key":"B43-20250825","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1681\/ASN.2018050518","article-title":"Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease","volume":"29","author":"Cassini","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B44-20250825","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1523-1755.2001.00065.x","article-title":"Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats","volume":"60","author":"Cowley","year":"2001","journal-title":"Kidney Int"},{"key":"B45-20250825","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease","volume":"14","author":"Zheng","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B46-20250825","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ekir.2021.03.893","article-title":"Enhanced MCP-1 release in early autosomal dominant polycystic kidney disease","volume":"6","author":"Janssens","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B47-20250825","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000502999","article-title":"Rapid progression of autosomal dominant polycystic kidney disease: Urinary biomarkers as predictors","volume":"50","author":"Messchendorp","year":"2019","journal-title":"Am J Nephrol"},{"key":"B48-20250825","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","article-title":"Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression","volume":"3","author":"Messchendorp","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B49-20250825","doi-asserted-by":"crossref","first-page":"e13951","DOI":"10.14814\/phy2.13951","article-title":"Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease","volume":"7","author":"Zimmerman","year":"2019","journal-title":"Physiol Rep"},{"key":"B50-20250825","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B51-20250825","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/0002-9343(87)90005-2","article-title":"Renal infection in autosomal dominant polycystic kidney disease","volume":"82","author":"Schwab","year":"1987","journal-title":"Am J Med"},{"key":"B52-20250825","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0272-6386(87)80036-7","article-title":"Renal infections in autosomal dominant polycystic kidney disease","volume":"10","author":"Sklar","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"B53-20250825","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7861\/clinmedicine.9-3-278","article-title":"Autosomal dominant polycystic kidney disease","volume":"9","author":"Chow","year":"2009","journal-title":"Clin Med (Lond)"},{"key":"B54-20250825","first-page":"161","article-title":"The influence of renal manifestations to the progression of autosomal dominant polycystic kidney disease","volume":"13","author":"Idrizi","year":"2009","journal-title":"Hippokratia"},{"key":"B55-20250825","first-page":"511","article-title":"Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease","volume":"17","author":"Ahmed","year":"2006","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B56-20250825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-14-1","article-title":"Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease","volume":"14","author":"Hwang","year":"2013","journal-title":"BMC Nephrol"},{"key":"B57-20250825","doi-asserted-by":"crossref","first-page":"19460","DOI":"10.1038\/s41598-020-76520-5","article-title":"Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3-5","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0004292021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:01:34Z","timestamp":1786478494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0004292021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0004292021","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2021-06-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}